It is a link to move within the page

Mainstay Products

Renal diseases and Hemodialysis

Torii mainly markets products related to hemodialysis in the area of renal diseases and Hemodialysis.
Riona Tablets (a hyperphosphatemia drug) that Torii launched in May 2014 is an oral drug for hyperphosphatemia for patients with CKD (dialysis/ peritoneum/conservative phase of kidney disease), and is the only water-soluble metallic salt-type therapeutic agent for hyperphosphatemia.
REMITCH CAPSULES (an oral antipruritic drug) that Torii launched in March 2009 is an oral selective opioid kappa receptor agonist for pruritus that is resistant to existing therapies (existing antipruritic drugs are not sufficiently effective) of patients on hemodialysis, and is highly evaluated as a therapeutic agent for pruritus for patients on hemodialysis.
Torii launched KAYEXALATE DRYSYRUP in February 2011 for improving the ease of taking KAYEXALATE Powder (agent for hyperkalemia). KAYEXALATE DRYSYRUP flavored with apple improves patients’ compliance and is highly evaluated in dialysis facilities.
In addition, FUTHAN for injection (protease inhibitor) developed by our company is an anticoagulant drug used during hemodiafiltration, and is used by patients on hemodialysis who have hemorrhagic lesions.

  • Riona Tablets
    Therapeutic agent for hyperphosphatemia
    Riona Tablets
  • REMITCH capsules
    Oral therapeutic agent for pruritus
    REMITCH capsules
  • KAYEXALATE
    Therapeutic agent for hyperkalemia
    KAYEXALATE
  • FUTHAN for injection
    Protease inhibitor
    FUTHAN for injection

Skin diseases

In the area of skin diseases, Torii markets products related to the treatment of skin diseases such atopic dermatitis and tinea pedis, and products related to allergens.
ANTEBATE has three dosage forms: ointment, cream, and lotion. It improves the symptoms of skin diseases such as atopic dermatitis and contact dermatitis by reducing inflammation. The availability of three dosage forms allows users to use each one depending on the disease, site, and symptoms. In addition, Torii has made efforts to improve the quality of life (QOL) of patients by improving the quality of the base and ease of use, and ANTEBATE is highly evaluated.

  • ANTEBATE
    Topical corticosteroid
    ANTEBATE

Allergens

In the area of allergens, Torii has produced and marketed products for the diagnosis and treatment of allergic diseases for about half a century, and currently markets 149 products for the diagnosis and treatment of 85 antigens as of December 2015.
CEDARTOLEN® SUBLINGUAL DROPS - Japanese Cedar Pollen launched by Torii in October 2014 are the first sublingual immunotherapy drug for Japanese Cedar Pollen.
In addition, MITICURE® House Dust Mite Sublingual Tablets launched by Torii in December 2015 is an allergen immunotherapy tablet for house dust mite allergy, for the indication of allergic rhinitis.

  • CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen
    Sublingual immunotherapy drug
    CEDARTOLEN® SUBLINGUAL DROP - Japanese Cedar Pollen
  • MITICURE® House Dust Mite Sublingual Tablets
    Allergen immunotherapy tablet
    MITICURE® House Dust Mite Sublingual Tablets

HIV infection

In the area of HIV infection, Torii markets products for the treatment of HIV (human immunodeficiency virus) disease, which causes AIDS (acquired immunodeficiency syndrome).
HIV mainly destroys lymphocytes to cause a decline in immune function and immunodeficiency.
Truvada® Combination Tablets was launched in Japan in April 2005. Two anti-HIV drugs contained in Truvada® Combination Tablets inhibit the proliferation of HIV by specifically inhibiting HIV reverse transcriptase. Multidrug therapy is the current standard therapy for HIV infection, and Truvada® Combination Tablets are recommended in the international treatment guidelines.
Stribild® Combination Tablets was launched in Japan in May 2013. With the launch of Stribild® Combination Tablets, which contains four compounds including anti-HIV drugs, the treatment of HIV infection with once daily administration has become possible in Japan for the first time. By improving convenience for patients, long-term adherence is expected to be maintained and improved.
Genvoya® Combination Tablets was launched in Japan in July 2016. Genvoya® Combination Tablets is a complete single tablet regimen which can treat HIV-1 infection with once-daily administration. Tenofovir disoproxil fumarate (TDF), one of four ingredients of Stribild® Combination Tablets, is replaced with tenofovir alafenamide (TAF) to compose “Genvoya® Combination Tablets”.
Descovy® Combination Tablets was launched in Japan in January 2017. Tenofovir disoproxil fumarate (TDF), one of two ingredients of Truvada® Combination Tablets, is replaced with tenofovir alafenamide (TAF) to compose “Descovy® Combination Tablets”.

  • Truvada® Combination Tablets
    Antiviral agent for HIV (anti-HIV drug)
    >Truvada® Combination Tablets
  • Stribild® Combination Tablets
    Antiviral agent for HIV (anti-HIV drug)
    Stribild® Combination Tablets
  • Genvoya® Combination Tablets
    Antiviral agent for HIV (anti-HIV drug)
    Genvoya® Combination Tablets
  • Descovy® Combination Tablets
    Antiviral agent for HIV (anti-HIV drug)
    Descovy® Combination Tablets

It is the end of the page